We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Jessica
Thut
Hyp-tr.elevate-asuc@nhs.net
Prof
Shaji
Sebastian
shaji.sebastian@hey.nhs.uk
Noninfective enteritis and colitis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Ulcerative colitis (UC) causes inflammation and ulceration on the inner lining of the colon (the large bowel). Sometimes, the condition can become so severe that a hospital admission is required (Acute Severe Ulcerative Colitis – ASUC). ASUC can be a life threatening condition for which specific treatment plans within the hospital setting are required. Unfortunately these treatment plans are largely ill-defined with approximately 30 - 40% of patients admitted with ASUC requiring emergency surgery to remove the large bowel (Colectomy). Colonoscopy (a small camera placed into the bowel) and various blood tests are used to assess the severity of the problem but these are not fully accurate in predicting risks and hence treatment can be very variable between clinicians and hospitals. This variability in practice can potentially impact on patient outcomes.
Intravenous corticosteroids is the mainstay of management but approximately 40% patients will not respond to the steroids. If steroids are not improving the condition then alternative treatments can be given such as Infliximab or cyclosporine and failing these emergency colectomy, which has additional risks.
Currently there are no ways to accurately predict which patients are likely to respond to steroids and /or rescue therapy within this setting. Hence healthcare professionals have no tools to ‘personalise’ care for ASUC by predicting up front which patients will fail initial medical therapy and thus predict those who may benefit form rescue therapy or early surgery.
This study will collect detailed ‘real time’ data from a large cohort of patients with ASUC across the UK to facilitate the development of a tool using the data from clinical, endoscopy and blood markers to predict treatment outcomes in ASUC and improve quality of care.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
- A diagnosis of Crohn's disease. - Admission for elective colectomy. - Infective colitis confirmed on stool culture, assays for Clostridium difficile or cytomegalovirus. - Inability to sign consent. - Prior colitis related surgery - pouch, stoma.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by HULL UNIVERSITY TEACHING HOSPITALS NHS TRUST and funded by HULL UNIVERSITY TEACHING HOSPITALS NHS TRUST; CROHN'S & COLITIS UK; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 42979
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
